Table 1

Serial electrophysiological findings

Baseline1 Week1 Month4 Months6 Months
Median nerve
 SAP (µV)NRNRNDNDNR
 DML (ms)4.05.55.24.94.9
 CMAP 1 (mV)7.30.20.92.73.8
 MCV (m/s)50.037.3ND40.339.5
 CMAP 2 (mV)7.50.1ND2.63.6
 F-wave (ms)33.0NDNDNDND
Ulnar nerve
 SAP (µV)NRNRNDNDNR
 DML (ms)2.84.34.24.34.8
 CMAP 1 (mV)151.40.83.35.7
 MCV (m/s)55.4ND30.336.537.5
 CMAP 2 (mV)11.1ND0.12.95.4
 MCV (m/s)55.6NDNDNDND
 CMAP 3 (mV)10.3NDNDNDND
 F-wave (ms)30.7NDNDNDND
Sural nerve
 SAP (µV)NRNDNDNDNR
Peroneal nerve
 DML (ms)3.65.3NRNRNR
 CMAP 1 (mV)6.42.3
 MCV (m/s)40.522.2
 CMAP 2 (mV)6.00.6
 MCV (m/s)40.0
 CMAP 3 (mV)6.0
  • Baseline recording was carried out three months after starting usage of levodopa/carbidopa intestinal gel. The other recordings were made at 1 and 4 weeks, 4 and 6 months after the onset of acute weakness.

  • CMAP 1, compound muscle action potential after distal stimulation; CMAP 2 is in the median nerve after elbow stimulation, in the ulnar nerve after below elbow stimulation and in the peroneal nerve after below fibular head stimulation; CMAP 3 is in the ulnar nerve after above elbow stimulation and in the peroneal nerve after above fibular head stimulation; DML, distal motor latency; MCV, motor conduction velocity; NR, not recordable, ND, not done; SAP, sensory action potential, SCV, sensory conduction velocity.